William Blair Investment Management LLC Has $41.45 Million Position in Insulet Corporation $PODD

William Blair Investment Management LLC reduced its stake in shares of Insulet Corporation (NASDAQ:PODD) by 50.3% in the 4th quarter, HoldingsChannel.com reports. The firm owned 145,811 shares of the medical instruments supplier’s stock after selling 147,692 shares during the quarter. William Blair Investment Management LLC’s holdings in Insulet were worth $41,445,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in the stock. Vanguard Group Inc. boosted its holdings in shares of Insulet by 1.0% during the third quarter. Vanguard Group Inc. now owns 8,796,200 shares of the medical instruments supplier’s stock worth $2,715,651,000 after purchasing an additional 87,845 shares during the period. Northern Trust Corp boosted its holdings in shares of Insulet by 0.5% during the third quarter. Northern Trust Corp now owns 709,180 shares of the medical instruments supplier’s stock worth $218,945,000 after purchasing an additional 3,618 shares during the period. Qube Research & Technologies Ltd boosted its holdings in shares of Insulet by 37.3% during the third quarter. Qube Research & Technologies Ltd now owns 574,365 shares of the medical instruments supplier’s stock worth $177,324,000 after purchasing an additional 156,009 shares during the period. Nordea Investment Management AB boosted its holdings in shares of Insulet by 35.0% during the fourth quarter. Nordea Investment Management AB now owns 551,133 shares of the medical instruments supplier’s stock worth $157,128,000 after purchasing an additional 142,922 shares during the period. Finally, Ameriprise Financial Inc. boosted its holdings in shares of Insulet by 0.8% during the third quarter. Ameriprise Financial Inc. now owns 494,712 shares of the medical instruments supplier’s stock worth $152,703,000 after purchasing an additional 4,057 shares during the period.

Insider Transactions at Insulet

In related news, Director Michael R. Minogue bought 2,030 shares of the company’s stock in a transaction that occurred on Wednesday, February 25th. The shares were acquired at an average price of $246.23 per share, with a total value of $499,846.90. Following the completion of the transaction, the director owned 17,483 shares of the company’s stock, valued at $4,304,839.09. The trade was a 13.14% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.36% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Canaccord Genuity Group cut their price objective on shares of Insulet from $435.00 to $249.00 and set a “buy” rating on the stock in a research report on Thursday, May 7th. Benchmark assumed coverage on shares of Insulet in a research report on Tuesday, May 12th. They set a “buy” rating on the stock. Piper Sandler cut their price objective on shares of Insulet from $360.00 to $210.00 in a research report on Wednesday, May 6th. Wall Street Zen raised shares of Insulet from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Finally, Robert W. Baird cut their price objective on shares of Insulet from $360.00 to $248.00 in a research report on Thursday, May 7th. Twenty-one analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Insulet has a consensus rating of “Moderate Buy” and an average target price of $254.96.

Insulet Stock Performance

NASDAQ:PODD opened at $154.87 on Monday. Insulet Corporation has a 12 month low of $145.59 and a 12 month high of $354.88. The firm has a market cap of $10.73 billion, a price-to-earnings ratio of 36.02, a P/E/G ratio of 1.22 and a beta of 1.20. The company has a quick ratio of 1.81, a current ratio of 2.49 and a debt-to-equity ratio of 0.71. The company’s 50 day moving average is $191.53 and its 200-day moving average is $250.80.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, beating analysts’ consensus estimates of $1.19 by $0.23. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The company had revenue of $761.70 million for the quarter, compared to analyst estimates of $729.89 million. During the same quarter last year, the firm posted $1.02 earnings per share. The company’s quarterly revenue was up 33.9% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.210- EPS. Equities analysts anticipate that Insulet Corporation will post 6.43 EPS for the current year.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.